Exposure to thimerosal in vaccines used in Canadian infant immunization programs, with respect to risk of neurodevelopmental disorders.
Bigham
M
M
British Columbia Centre for Disease Control, Vancouver, British Columbia.
Copes
R
R
Srour
L
L
D001321:Autistic Disorder / Q000139:chemically induced; D004781:Environmental Exposure / Q000009:adverse effects*; D017325:Hepatitis B Vaccines / Q000009:adverse effects*; D006801:Humans; D008628:Mercury / Q000009:adverse effects*; D009422:Nervous System Diseases / Q000139:chemically induced*; D011310:Preservatives, Pharmaceutical / Q000009:adverse effects* / Q000737:chemistry; D012307:Risk Factors; D013849:Thimerosal / Q000009:adverse effects* / Q000737:chemistry
D017325:Hepatitis B Vaccines; D011310:Preservatives, Pharmaceutical; D013849:Thimerosal; D008628:Mercury